Guidelines on SARS should be refined

June 19, 2003

Current World Health Organisation (WHO) guidelines for diagnosing suspected SARS may not be sufficiently sensitive in assessing patients before admission to hospital, suggest researchers from Hong Kong in this week's BMJ.

The study took place in a newly opened SARS screening clinic at the Prince of Wales Hospital in Hong Kong from 12-31 March 2003, and involved 556 hospital staff, patients, and relatives who had had contact with someone with SARS. Of the 556 people, 141 were admitted to hospital, and 97 had confirmed SARS.

The WHO guidelines currently emphasise respiratory tract symptoms such as cough, shortness of breath, and breathing difficulty. But the team found that these symptoms did not feature strongly in the early stages of the illness. Instead, symptoms such as fever, chills, loss of appetite, vomiting, and diarrhoea, were significantly more common among the 97 patients.

In screening patients for SARS, these symptoms may be better indications than the symptoms listed in the WHO guidelines, which were based on patients who were already in hospital, say the authors.

The WHO guidelines also emphasise temperature readings of 38C or more, but over half of cases did not have such levels of fever during the pre-hospital screening phase, they add.

"The WHO criteria should be refined to include routine daily follow up, documentation of non-respiratory systemic symptoms, and daily chest radiography until patients have passed at least 48 hours without symptoms," they conclude.

In a second study at the same hospital, researchers found abnormal blood cell counts in patients with SARS. For instance, of 157 patients assessed, 98% developed lymphopenia (a decrease in numbers of lymphocytes in the blood), and 55% developed thrombocytopenia (a decrease in the number of blood platelets).

Studies of the effect of SARS on various body systems are crucial to the understanding of this disease, say the authors, and further studies to evaluate the mechanisms of these changes are needed.
-end-


BMJ

Related SARS Articles from Brightsurf:

SARS-CoV-2 mutations do not appear to increase transmissibility
None of the mutations currently documented in the SARS-CoV-2 virus appear to increase its transmissibility in humans, according to a study led by UCL researchers, published in Nature Communications.

Replication cycle of SARS-CoV-2 in 3D
Researchers have studied SARS-CoV-2 replication in cells and obtained detailed insights into the alterations induced in infected cells.

Folding of SARS-CoV2 genome reveals drug targets -- and preparation for 'SARS-CoV3'
For the first time, an international research alliance has observed the RNA folding structures of the SARS-CoV2 genome with which the virus controls the infection process.

Antibodies to SARS-CoV-2 are detected up to 3 months after infection
The follow-up study in health care workers of the Hospital Clinic de Barcelona hopes to provide information on the duration of different antibodies to SARS-CoV-2 and their role in protecting from disease and reinfection

New SARS-CoV-2 test is a simple, cost-effective, and efficient alternative for SARS-CoV-2 testing
Scientists from Northwell Health Laboratories have developed a new diagnostic multiplex assay that can be used for epidemiological surveillance and clinical management of COVID-19.

Immunological memory after cured Sars-CoV-2 infection
After recovery from SARS-CoV-2 infection, immune cells are formed which remain in the body and could mediate a rapid immune response in case of re-infection.

Hospital-acquired SARS-CoV-2 infection
The rare incidence of nosocomial SARS-CoV-2 infection is reviewed in this Viewpoint, which also discusses ways it can be minimized, including use of surgical masks, proper ventilation, physical distancing, eye protection, regular testing and the availability of sick leave for health care workers.

Peering under the "hood" of SARS-CoV-2
Microscope and protein data are incorporated into an easy-to-use-and-update tool that can model an organism's 3D appearance.

Nanobodies that neutralize SARS-CoV-2
Two separate studies have identified nanobodies - which could be produced less expensively than monoclonal antibodies - that bind tightly to the SARS-CoV-2 spike protein and efficiently neutralize SARS-CoV-2 in cells.

Global study identifies common vulnerabilities across SARS-CoV-2, SARS-CoV-1 and MERS coronaviruses
There are common vulnerabilities among three lethal coronaviruses, SARS-CoV-2, SARS-CoV-1 and MERS-CoV, such as frequently hijacked cellular pathways, that could lead to promising targets for broad coronavirus inhibition, according to a study by an international research team that includes scientists from the Institute for Biomedical Sciences at Georgia State University.

Read More: SARS News and SARS Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.